Q02763 (TIE2_HUMAN) Homo sapiens (Human)
Angiopoietin-1 receptor UniProtKBInterProSTRINGInteractive Modelling
It is possible new templates exist for this target since these models were created.
Available Structures
16 Experimental Structures
Description | PDB ID | Oligo-state | Range | Ligands | ||
---|---|---|---|---|---|---|
Structural basis for angiopoietin-1 mediated signaling initiation |
Heteromer Q15389; | |||||
Assess | ||||||
Angiopoietin-2/Tie2 Complex Crystal Structure |
Heteromer O15123; | 1×NAG; 2×NAG; 1×CA; 1×NAG; 2×SO4; | ||||
Assess | ||||||
Crystal structure of Tie2-agonistic antibody in complex with human Tie2 Fn2-3 |
Heteromer | 22×EDO; | ||||
Assess | ||||||
Crystal structure of the membrane proximal three fibronectin type III (FNIII) domains of Tie2 (Tie2… | homo-2-mer | |||||
Assess | ||||||
Homodimerization of Tie2 Fibronectin-like domains 1-3 in space group C2 | homo-2-mer | 1×NAG; 1×NAG; 1×NAG; 4×NAG; | ||||
Assess | ||||||
Homodimerization of Tie2 Fibronectin-like domains 2 and 3 in space group P21 | homo-2-mer | 1×NAG; 1×NAG; 4×NAG; | ||||
Assess | ||||||
Tie2 Ligand-Binding Domain Crystal Structure | monomer | 1×NAG; 4×NDG; 4×SO4; | ||||
Assess | ||||||
TIE2 KINASE DOMAIN | monomer | |||||
Assess | ||||||
Crystal structure of cytoplasmic kinase domain of Tie2 complexed with inhibitor CEP11207 | monomer | 1×0CE; | ||||
Assess | ||||||
CRYSTAL STRUCTURE OF TIE2 IN COMPLEX WITH DECIPERA COMPOUND DP1919 | monomer | 2×SO4; 1×919; | ||||
Assess | ||||||
Structure of the Tie2 kinase domain in complex with a thiazolopyrimidine inhibitor | monomer | 1×QQ1; | ||||
Assess | ||||||
Synthesis, Structural Analysis, and SAR Studies of Triazine Derivatives as Potent, Selective Tie-2 … | monomer | 1×RAJ; | ||||
Assess | ||||||
Selection of fragments for kinase inhibitor design: decoration is key | monomer | 1×3WR; | ||||
Assess | ||||||
Evolution of a highly Selective and Potent 2-(Pyridin-2-yl)-1,3,5-triazine Tie-2 Kinase Inhibitor | monomer | 1×MR9; | ||||
Assess | ||||||
Synthesis, Structural Analysis, and SAR Studies of Triazine Derivatives as Potent, Selective Tie-2 … | monomer | 1×MUH; | ||||
Assess | ||||||
cFMS tyrosine kinase (tie2 KID) in complex with a pyrimidinopyridone inhibitor | monomer | 3×SO4; 1×IXH; | ||||
Assess |
4 SWISS-MODEL models
Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
1fvr.1.A | monomer | 0.76 | 100.00 | |||
Assess | ||||||
5utk.1.A | monomer | 0.73 | 99.33 | |||
Assess | ||||||
4k0v.1.A | monomer | 0.64 | 99.81 | |||
Assess | ||||||
3uto.2.A | monomer | 0.52 | 20.25 | |||
Assess |
8 SWISS-MODEL models built on isoform sequence
Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
---|---|---|---|---|---|---|
Isoform 2 | 2wqb.1.A | monomer | 0.74 | 1×QQ1; | 99.69 | |
Assess | ||||||
Isoform 2 | 5mya.1.A | monomer | 0.73 | 100.00 | ||
Assess | ||||||
Isoform 2 | 4k0v.1.A | monomer | 0.62 | 99.37 | ||
Assess | ||||||
Isoform 2 | 3uto.2.A | monomer | 0.52 | 20.56 | ||
Assess | ||||||
Isoform 3 | 1fvr.1.A | monomer | 0.77 | 100.00 | ||
Assess | ||||||
Isoform 3 | 5utk.1.A | monomer | 0.75 | 99.33 | ||
Assess | ||||||
Isoform 3 | 4k0v.1.A | monomer | 0.58 | 96.90 | ||
Assess | ||||||
Isoform 3 | 3uto.2.A | monomer | 0.53 | 20.30 | ||
Assess |